Below are the most recent publications written about "Telangiectasis" by people in Profiles.
-
van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, Müller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Ellen Csuka M, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013 Nov 1; 72(11):1747-55.
-
Bendell JC, Gordon MS, Hurwitz HI, Jones SF, Mendelson DS, Blobe GC, Agarwal N, Condon CH, Wilson D, Pearsall AE, Yang Y, McClure T, Attie KM, Sherman ML, Sharma S. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Clin Cancer Res. 2014 Jan 15; 20(2):480-9.
-
Noda S, Lee JB, Li K, Schwartz L. Unilateral telangiectasia macularis eruptiva perstans with a clear demarcation at the midline of the trunk. Eur J Dermatol. 2012 May-Jun; 22(3):407-8.
-
Thieu KP, Haynes HA. Generalized essential telangiectasia with predilection for surgical scar. J Am Acad Dermatol. 2009 Apr; 60(4):710-1.
-
Mitchell EP, Perez-Soler R, Van Cutsem E, Lacouture ME. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities. Oncology (Williston Park). 2007 Oct; 21(11 Suppl 5):4-9.
-
Kaul V, Friedenberg FK, Braitman LE, Anis U, Zaeri N, Fazili J, Herrine SK, Rothstein KD. Development and validation of a model to diagnose cirrhosis in patients with hepatitis C. Am J Gastroenterol. 2002 Oct; 97(10):2623-8.